Search by Job Title

Research Associate Scientist - Molecular VirologyNovira Therapeutics

THIS JOB HAS EXPIRED

Description
We are seeking a highly motivated and productive research associate scientist with excellent hands-on cell
biology and molecular virology skill sets. The selected candidate will assist in the development and
establishment of innovative methods and technologies for the study of HBV life cycle. This is a contract
position with the possibility of converting to a full-time position within the research group.
Qualifications
? Master of Science comparable or higher with at least 3 years of experience as independent research
associate in virology, molecular and cell biology, biochemistry, immunology or related discipline.
? Individuals with hands-on molecular virology experience in HBV biology will be preferred.
? Experience in drug discovery, assay development, and moving antiviral or immunomodulatory agents
from discovery to clinical stage will be preferred.
? Additional experience with immunology, flow cytometry, electron microscopy will be an advantage.
? Must be able to conduct innovative research experiments, including troubleshooting outcomes and
designing follow-on studies with minimal supervision.
? Proficiency in data analysis and presentation tools, excellent written and oral communication skills.
? Provide timely updates of research progress to research teams.
? Possess the ability to balance multiple projects, be collaborative and productive in a small team
environment.
? Possess a high level of research skills and a strong desire to learn new areas in a highly dynamic and
transparent research organization.
? Must be able and willing to work with infectious agents, chemical and radioactive substances.
Who We Are
Novira Therapeutics is a venture-backed biotechnology company focused on the development and
commercialization of a novel class of antiviral therapeutics. The two lead programs address chronic
Hepatitis B infection and HIV, diseases with enormous worldwide significance, unmet needs, and billion
dollar market potential.
Novira?s oral drugs target the capsid of the virus, and offer a promising treatment option both as
monotherapy and in combination with current standards of care. HBV afflicts over 350 million people
worldwide, with only a single oral class of drugs available. The company?s antivirals potentially address
limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available,
polymerase inhibitors, are rarely curative and often require lifelong treatment, as well as in chronic HIV
infection, a disease for which the continued ability of the virus to mutate inevitably leads to drug-resistant
viral strains. Each of these limitations to the standard of care can potentially be addressed by capsid
inhibitors which feature a new mechanism of action.
In August 2012 the company secured a $23 million Series A financing co-led by new investors 5AM
Ventures and Canaan Partners and joined by WuXi PharmaTech as well as existing investors BioAdvance,
Mid-Atlantic Angel Group, Robin Hood Ventures and Delaware Crossing Investment Group (DCIG). With
this recent financing the company has substantial resources to develop these first-in-class therapies that
offer the promise to substantially improve outcomes in HBV and HIV patients.
Located in the greater Philadelphia area, the company is managed by a team of world class scientific
experts who are making rapid progress with Novira?s lead programs. Given the growing interest of HBV
by numerous pharmaceutical companies and its prevalence in Asia, Novira Therapeutics has begun to
attract the attention of potential corporate partners. With the company on track to enter the clinic in the
beginning of 2014 and the potential for near-term partnering opportunities, the company well is poised to
emerge as a leader in the antivirals arena.